Corporate Presentation 2021 - RYAH
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Corporate Presentation 2021
Certain information set forth in this presentation management’s beliefs and opinions in respect of the
contains “forward-looking information”, including future so that they may use such beliefs and opinions
“future-oriented financial information” and “financial as one factor in evaluating an investment.
outlook”, under applicable securities laws (collectively
referred to herein as forward-looking statements). These statements are not guarantees of future
performance and undue reliance should not be
Except for statements of historical fact, the placed on them. Such forward-looking statements
RYAH MedTech - Investor Presentation
information contained herein constitutes forward- necessarily involve known and unknown risks
looking statements and includes, but is not limited and uncertainties, which may cause actual
to, the (i) projected financial performance of the
Company; (ii) completion of, and the use of proceeds
from, the sale of the shares being offered hereunder;
performance and financial results in future periods
to differ materially from any projections of future
performance or result expressed or implied by such Forward-
Looking
(iii) the expected development of the Company’s forward-looking statements.
business, projects, and joint ventures; (iv) execution of
the Company’s vision and growth strategy, including Although forward-looking statements contained in
with respect to future M&A activity and global this presentation are based upon what management
Statements
growth; (v) sources and availability of third-party of the Companybelieves are reasonable assumptions,
financing for the Company’s projects; (vi) completion there can be no assurance that forward-looking
of the Company’s projects that are currently statements will prove to be accurate, as actual
underway, in development or otherwise under results and future events could differ materially from
consideration; (vi) renewal of the Company’s current those anticipated in such statements. The Company
customer, supplier and other material agreements; undertakes no obligation to update forward-looking
and(vii) future liquidity, working capital, and capital statements if circumstances or management’s
requirements. estimates or opinions should change except as
required by applicable securities laws. The reader is
Forward-looking statements are provided to allow cautioned not to place undue reliance on forward-
potential investors the opportunity to understand looking statements.
2
Who 4. Data usage in research and
We Are
further development
1. Dose-measuring
RYAH MedTech - Investor Presentation
Delivery
Through our cutting-edge Mechanism
IoT product suite, we capture 3. Data analytics
powerful data insights which can and processing
then be leveraged by users, clinical
researchers, and producers.
RYAH furthers its path to capture the Internet of
Things (IoT) and Big Data Market. With an industry
projected to reach USD $411.2 billion by 2026,
RYAH continues to innovate by incorporating AI data
analytics into plant based treatments.
We strive to make dosage control for plant-based
medicine a far more reliable and remote medical
technology which can then be used to inform critical
elements of your health and wellness decisions. 2. Patient use and
data capture
Source: polarismarketresearch.com/press-releases/herbal-
medicine-market
3
Market
Pain Points
RYAH MedTech - Investor Presentation
Where does RYAH fit into all of this?
Innovation:
Regulation: ▸ Not enough functioning
▸ Lack of admissible data
data platforms
▸ Limited solutions
▸ Machine learning is
providing control
underused
Big Pharma: Market Knowledge:
▸ Unreliable session review ▸ Lack of uniformity
▸ Lack of consistent research ▸ Poor patient feedback
▸ Limited ways to integrate ▸ Existing data is
existing data unstructured
4
DATA
INPUT
A Data-
IoT Devices QR Code & NFC Tag Security Dose Measuring
Tech-embedded ecosystem Ensures safe functionality Empowers user control
of products operates as a and prevents product when administering
uniform network tampering products
Driven
RYAH MedTech - Investor Presentation
Approach DATA
RYAH’s state-of-the-art IoT
product suite fuses together
medicine and data technology
using machine learning
and artificial intelligence to
provide users with plant-
based treatments tailored to
their needs and experiences. DATA
ACCESS
AI Analytics Apps & Software Review Mechanism
Provides consistent Cutting-edge technology User statistics and
and structured data for produces valuable feedback give credibility
regulators, users, and clinics. information for users to the experience
5
Data Analytics Platform
RYAH Mobile Apps RYAH MD RYAH Data Analytics Dashboard
RYAH
CLOUD
Patients Physicians & Clinics Big Pharma, Universities, Governments
RYAH MedTech 6 Investor Presentation
RYAH IoT
RYAH MedTech - Investor Presentation
RYAH Smart Inhaler
A dry herb inhaler with an integrated volumetric
RYAH Smart Patch Product
Suite
A lightweight, mobile-controlled smart
airflow sensor that gives consumers the ability to patch that can be boosted for on-demand
track and control exactly how much they inhale. dose control.
We’ve evolved from PotBot and
transformed our data collection
capabilities to create the first
ever IoT solution that captures
seed-to-consumption data.
RYAH Smart Pen RYAH MD Platform
A multi-liquid chamber pen that precisely RYAH MD is a platform for doctors to remotely
dispenses up to three different formulations at monitor and control their patients’ dosing regimen
once for a dose-controlled entourage effect. with RYAH’s suite of dose-measuring products.
7
Target Market:
Seed to Consumption
By working with multiple players in the ecosystem, RYAH empowers
RYAH MedTech - Investor Presentation
multiple stages in the cycle of plant-based treatment and provides
the necessary tools for researchers to improve their trials, and for
producers to improve the quality of their formulations.
Researchers
Exploring new treatments utilizing RYAH devices and technology
Clinical Trials
Testing, validating, and formalizing treatment effects using
all-encompassing data
Dispensaries and Growers
Filling cartridges and selling devices to patients
Patients
Interacting with RYAH products and logging their
experiences, thus providing data for further processing.
8
Business Model
1 2 3 4
Formulation Partner or Clinic RYAH develops a custom mobile Formulation Partner fills Patients receive
establishes partnership with app for the trial and provides RYAH accessories devices and medicine
RYAH and registers patients devices and cartridges
5 6 7 8
Consumers use RYAH dose- Patients provide obligatory HIPAA-compliant data is Data returns to Clinic and
measuring devices reviews via mobile app registered in the backend Formulation Partner for
further use
RYAH MedTech 9 Investor Presentation
Clinical Case Study
RYAH is the selected device for the world’s largest
RYAH MedTech - Investor Presentation
clinical studies in plant-based treatment conducted
out of the UK.
Duration: Patients: Ailment:
5 Years 50,000+ Chronic Pain
Software:
Medicine: Cartridge order:
Custom
19 Tons Millions
Mobile app
The study aims to:
▸ Establish safety and efficacy of plant based medicine
▸ Advance evidence-based policymaking based on the ability to capture
medically-relevant seed-to-consumption data on cannabis treatment
10Nutraceuticals
Dose control provided by RYAH Smart
Patch is a perfect match for the wide range
of nutraceuticals formulations.
RYAH MedTech - Investor Presentation
On Demand Personal and Easy Usage
Boost Community Stats Tracking
Preventive and Higher
Wellness Use Bioavailability
RYAH’s suite of IoT devices are designed for multiple formulations
and a wide variety of adminstration routes, making it a turn key
solution for clinic, pharmacy and doctor partnerships.
11Uniquely Positioned
For Market Share
RYAH incorporates big data into plant-based treatment, thus
creating a unique cross point where several growing markets
are connected.
RYAH MedTech - Investor Presentation
Hardware & Software
Big Data: $229.4B USD by 2025
IoT: $1.6T USD by 2025
Health & Wellness
Plant-based Treatment: $27B USD by 2026
Nutraceuticals: $226B USD by 2024
12Key Figures
Gregory Wagner Jordan Medley
MBA, Chief Executive Officer Director of Product Operations
Jeannine Zimmerman Sofiya Kleshchuk
Chief Financial Officer Client Relations Specialist
RYAH MedTech 13 Investor PresentationIn the
RYAH MedTech - Investor Presentation
Media
Over the years, RYAH’s
predecessor companies have
been repeatedly features in
many media outlets.
The team behind PotBot and RYAH are highly
lauded across multiple news channels, equating
to a higher brand authority within the data and
medical technology space.
14Patents & Safety
The First Cannabis Patent in the AI Industry
INTELLECTUAL PROPERTY
RYAH MedTech - Investor Presentation
AI Ontology: Utility RYAH Filling Line: Design
Patent Number 10296714: Issued Application Pending
Filed May 2016 June 2019
RYAH Smart Inhaler: Utility RYAH Cartridge: Design
Patent Number 15/924172: Pending Patent Number 62/809266: Pending
Filed March 2018 Filed April 2019
RYAH Mouthpiece: Design RYAH Patch & Pen: Design
Patent Number 62/809266: Pending Application Pending
Filed April 2019 June 2019
SAFETY
Completed Planned
▸ IEC 60601 medical device ▸ Health Canada Class II medical device
safety test (Inhaler) certification (Inhaler)
▸ Health Canada class Pending
I medical device ▸ IEC 60601 medical device safety test (Patch)
certification (Cartridges) ▸ EU Medical device registration (MDR) (Inhaler)
▸ FCC Mark (Inhaler) ▸ Australia ARTG medical device registration
▸ CE Mark (Inhaler) (Inhaler)
15ryahgroup.com | info@ryah.com
LEGAL AUDITORS
RUSKIN MOSCOU FALTISCHEK, P.C. GARFINKLE BIDERMAN LLP DALE MATHESON CARR-HILTON LABONTE LLP
1425 Rexcorp Plaza, Glenn Curtiss Blvd Dynamic Funds Tower, Suite 801 CHARTERED PROFESSIONAL ACCOUNTANTS
Uniondale, NY 11556, United States 1 Adelaide Street East 1500-1140 W. Pender St.
1 516-663-6600 Toronto, Ontario M5C 2V9 Vancouver, BC V6E 4G1
Corporate Presentation 2021You can also read
